New IPF drug HEC585 enters Mid-Stage trial
NCT ID NCT05060822
First seen Apr 22, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests a new tablet called HEC585 for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. About 270 adults aged 40-80 will take either HEC585, a placebo, or an existing drug (pirfenidone) for 24 weeks. The main goal is to see if HEC585 helps maintain lung function better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.